Should targeting albuminuria be part of a cardiovascular risk reduction paradigm?

Cardiology Clinics
Adam T Whaley-Connell, Rigas G Kalaitzidis

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States as well as the rest of the world. Chronic kidney disease (CKD) is considered a CVD risk equivalent. The development of albuminuria has been identified as an additional possible risk marker that is almost unique to patients with CKD and a marker for predicting CVD risk. This review focuses on clinical and epidemiologic evidence regarding the role of albuminuria in the context of CVD development. It reviews the association of albuminuria with other comorbidities associated with increased cardiovascular risk and the modalities aimed at the reduction of albuminuria and maximizing of cardiovascular risk reduction.

References

Apr 1, 1989·Diabetologia·T DeckertA Kofoed-Enevoldsen
Sep 28, 1996·BMJ : British Medical Journal·P RossingH H Parving
Nov 13, 1998·The New England Journal of Medicine·G Remuzzi, T Bertani
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Oct 3, 2002·Circulation·Hans L HillegeUNKNOWN Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group
Mar 12, 2003·Circulation·J Malcolm O ArnoldUNKNOWN HOPE Investigators
Dec 25, 2003·Diabetes Care·Mark E MolitchUNKNOWN American Diabetes Association
Apr 29, 2004·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·UNKNOWN Kidney Disease Outcomes Quality Initiative (K/DOQI)
Oct 16, 2004·Kidney International. Supplement·Robert C AtkinsSteven J Chadban
Oct 20, 2004·Circulation·Folkert W AsselbergsUNKNOWN Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators
Nov 2, 2004·The New England Journal of Medicine·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
Nov 26, 2004·Journal of the American Society of Nephrology : JASN·Josef CoreshThomas H Hostetter
Nov 16, 2005·Hypertension·George L BakrisUNKNOWN GEMINI Investigators
Jul 11, 2006·Journal of the American Society of Nephrology : JASN·Dick de ZeeuwRobert H Henning
Jul 11, 2006·Journal of the American Society of Nephrology : JASN·Coen D A Stehouwer, Yvo M Smulders
Nov 21, 2007·Circulation·Scott D SolomonUNKNOWN Prevention of Events With ACE Inhibition (PEACE) Investigators
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Jun 27, 2008·Journal of the American Society of Nephrology : JASN·John P FormanGary C Curhan
Jul 11, 2008·Mayo Clinic Proceedings·John Danziger
Aug 13, 2008·Current Opinion in Nephrology and Hypertension·Irena Duka, George Bakris
Nov 4, 2008·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Tom D J SmildeHans L Hillege
Mar 6, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Sadayoshi ItoTakefumi Mori
Apr 24, 2009·Journal of Hypertension·Thomas SehestedtMichael H Olsen
May 16, 2009·Journal of the American Society of Nephrology : JASN·Toshiharu NinomiyaUNKNOWN ADVANCE Collaborative Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Cardiology Clinics
Tamar S Polonsky, Francesco Locatelli
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
Roland E SchmiederMichael Böhm
European Journal of Heart Failure
Colette E JacksonALiskiren Observation of heart Failure Treatment (ALOFT) investigators
© 2021 Meta ULC. All rights reserved